Catalyst Event
AbbVie Inc (ABBV) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
4/27/2026, 12:00:00 AM
Submitted an application to the U.S. FDA for SKYRIZI (risankizumab) for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn's disease.
Korean Translation
중등도에서 중증의 활동성 크론병 성인 환자 치료를 위한 스카이리치(리산키주맙)의 피하 유도 요법에 대한 허가 신청서를 미국 FDA에 제출함.
Related Recent Events
WuXi Biologics (Cayman) Inc (2269) · Other
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
12/18/2026, 12:00:00 AM
WuXi AppTec Co Ltd (2359) · Other
Ex-dividend date on May 13, 2026, for the 2025 final cash dividend of RMB 1.57927 per share (RMB 15.7927 per 10 shares); low impact estimated as price typically adjusts by the dividend amount, scheduled.
5/13/2026, 12:00:00 AM
Gilead Sciences Inc (GILD) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-07. This event is estimated to have a high price impact as quarterly results often drive significant market volatility scheduled.
5/7/2026, 12:00:00 AM
Kenvue Inc (KVUE) · Earnings Release
Kenvue will announce its first quarter 2026 financial results before the market opens on May 7, 2026. Based on historical earnings volatility, a 5% price impact is expected.
5/7/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer is scheduled to release its Q1 2026 earnings results before the market opens on May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM
Vertex Pharmaceuticals Inc (VRTX) · Earnings Release
Vertex Pharmaceuticals is scheduled to announce its first-quarter 2026 financial results after the market closes on May 4, 2026. This earnings release is estimated to have a >=5% price impact, scheduled
5/4/2026, 12:00:00 AM